Loading...

Home
ETF
KROS

KROS

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

KROS News

Five Low Price-to-Book Stocks to Buy: AES, BorgWarner, Enersys, PG&E, Keros

Jan 02 2026NASDAQ.COM

Zacks.com Spotlights StoneCo, General Motors, Enersys, Deutsche, and Keros

Dec 16 2025NASDAQ.COM

Reasons to Consider Keros Therapeutics, Inc. (KROS) as a Strong Momentum Stock: Is It Time to Buy?

Dec 12 2025NASDAQ.COM

B of A Securities Keeps Neutral Rating on Keros Therapeutics (KROS)

Nov 29 2025NASDAQ.COM

B of A Securities Keeps Neutral Rating on Keros Therapeutics and Increases Price Target to $19

Nov 28 2025Benzinga

Keros Therapeutics Reveals Initial Findings from Tender Offer

Nov 19 2025Newsfilter

Keros Therapeutics Launches Tender Offer to Buy Back Up to $194.4 Million in Shares

Oct 20 2025Newsfilter

Keros Therapeutics Launches Tender Offer to Buy Back Up to $194.4 Million in Shares

Oct 20 2025SeekingAlpha

ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal

Aug 21 2025Newsfilter

Keros Receives U.S. FDA Orphan Drug Designation for KER-065 in Duchenne Muscular Dystrophy Treatment

Aug 20 2025Newsfilter

Keros Therapeutics' Treatment for Duchenne Muscular Dystrophy Receives Orphan Drug Designation from FDA

Aug 20 2025NASDAQ.COM

Keros To Receive Milestone Payment Under License Agreement With Takeda

Jul 17 2025NASDAQ.COM

Fat, not muscle: drugmakers in race for next weight-loss breakthrough

Jun 18 2025Reuters

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

Jun 10 2025Benzinga

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Jun 09 2025Newsfilter

Keros to Return $375 Million to Shareholders Following Strategic Review

Jun 09 2025Yahoo Finance